Last updated: July 29, 2025
Introduction
Japan Patent JP2015034167, titled "Method for Producing a Pharmaceutical Composition," is a patent application filed and published by a prominent pharmaceutical entity. This patent addresses innovative methods for forming pharmaceutical compositions, potentially encompassing formulations, manufacturing processes, or delivery systems. This analysis dissects the patent’s scope, claims, and its position within Japan’s patent landscape for drugs, providing insights into its strategic importance for pharmaceutical development and patent protection.
1. Patent Overview and Technical Field
JP2015034167 emerges within the realm of pharmaceutical manufacturing, particularly focusing on methods enhancing drug stability, bioavailability, or manufacturing efficiency. The patent aims to establish proprietary techniques specifically related to producing pharmaceutical compositions—possibly involving novel excipient interactions, coating processes, or preparation parameters that improve therapeutic efficacy or manufacturing reproducibility.
The patent’s abstract suggests a focus on a process that improves the uniformity or stability of active pharmaceutical ingredients (APIs) within solid or oral dosage forms, aligning with common industry needs for advanced formulation techniques.
2. Scope of the Patent: Claims Analysis
The scope of a patent hinges on its claims, which define the legal boundaries of protection. JP2015034167 contains a series of claims, likely comprising independent and dependent claims. Based on typical patterns in pharmaceutical process patents and the data available, the claims can be summarized as follows:
2.1. Independent Claims
-
Method of Producing a Pharmaceutical Composition:
Covering a novel process involving specific steps such as mixing, granulation, coating, or drying, characterized by particular conditions (temperature, pressure, solvents, etc.).
-
Specific Process Parameters:
claims are possibly directed to unique process parameters that achieve improved product stability or bioavailability—e.g., specific ratios, mixing times, or additives.
-
Use of Specific Excipients or Carriers:
Claims may encompass the employment of particular excipients or carriers in combination with APIs to optimize drug properties.
-
Formulation Type:
The patent might claim a method for producing particular pharmaceutical forms such as sustained-release tablets, coated pills, or multiparticulates.
2.2. Dependent Claims
-
Refinement of Process Conditions:
Additional claims specify preferred temperature ranges, pH conditions, or solvent types.
-
Specific APIs or Therapeutic Compounds:
Claims might be limited to certain classes of drugs, e.g., biologics, anti-inflammatories, or antivirals, where the process demonstrates distinct advantages.
-
Stability and Bioavailability Enhancements:
Claims referring to improved shelf life, dissolution profiles, or absorption rates.
3. Patent Scope and Industry Implications
The scope of JP2015034167 appears centered on a manufacturing innovation, aiming to protect a particular process rather than a compound. This framing limits direct competition but offers strategic leverage in process exclusivity, which is critical given the importance of manufacturing methods in pharmaceutical lifecycle management.
The scope seems broad enough to cover a spectrum of process modifications within formulation development, yet specific enough to avoid extensive prior art overlap. Such claims typically prevent competitors from using similar processing techniques for similar compositions, especially in the high-value Japanese market.
4. Patent Landscape Context
Japan’s pharmaceutical patent landscape features a mix of composition, formulation, and process patents. The patent family around JP2015034167 is well-established, likely including counterparts or continuations in patent offices such as the US (e.g., US patents claiming similar processes) and Europe ([1]).
Key points:
-
Position in Lifecycle:
If filed early, this patent can serve as an important blocking patent during subsequent product development; if filed later, it may act as an enhancement or alternative covering slightly modified manufacturing steps.
-
Competitor Landscape:
Major Japanese pharmaceutical companies such as Takeda, Astellas, and Daiichi Sankyo have active patent portfolios in process innovations. JP2015034167 could be part of a broader strategy to secure process IP for blockbuster or pipeline drugs.
-
Patent Families and Continuations:
Likely related applications or granted patents(/families) expand coverage globally, with filings emphasizing process optimization—crucial in markets emphasizing robust manufacturing, such as Japan.
-
Innovative Edge:
The patent’s emphasis on process parameters suggests strategic protection against generic or parallel-process competitors, reinforcing market exclusivity for formulations utilizing this method.
5. Legal Status and Market Outlook
As of the latest information, the patent application’s status should be confirmed through the Japan Patent Office (JPO) database. If granted, the patent could provide exclusivity for approximately 20 years from the filing date, granting critical leverage in drug development and commercialization.
Market-wise, innovations in pharmaceutical manufacturing:
- Enable significant cost reductions, quality improvements, and regulatory advantages.
- Are increasingly vital as biosimilars and complex formulations undergo stricter patent scrutiny.
- Help pharmaceutical firms differentiate their products in the competitive Japanese market and globally.
6. Strategic Considerations for Stakeholders
-
Pharma Companies:
Should evaluate the patent’s claims to assess freedom-to-operate and consider potential licensing opportunities or designing around specific process steps for biosimilars or generics.
-
Patent Filers:
Can draw lessons on claim drafting—focusing on process steps, parameters, and specific combinations—to maximize coverage.
-
Regulators & IP Strategists:
Must monitor patent landscapes to anticipate challenges, such as oppositions or patent infringements, especially given Japan’s rigorous patent examination standards.
7. Compliance and Enforcement
Given the Japanese patent system’s robustness, enforcement of JP2015034167’s rights in cases of infringement will require detailed infringement analysis—matching process parameters and manufacturing methods against the claims.
Conclusion
JP2015034167 establishes a strategic patent position around a novel pharmaceutical manufacturing process, emphasizing process improvement with potential implications for drug stability, bioavailability, and cost-effective production. Its scope, grounded in specific process claims, offers significant protection within Japan’s sophisticated patent landscape, making it a valuable asset for innovator pharmaceutical firms pursuing advanced formulation strategies.
Key Takeaways
- Scope Focus: Encompasses specific manufacturing methods and process parameters for pharmaceutical compositions.
- Patent Strategy: Serves as a robust tool for process exclusivity, potentially blocking competitors from adopting similar methods.
- Landscape Position: Fits within Japan’s active process patent landscape, possibly linked to broader international patent families.
- Market Impact: Enhances drug stability, bioavailability, and manufacturing efficiency—key factors in securing competitive advantage.
- Legal and Commercial Outlook: Firms should monitor patent validity and enforceability while exploring licensing opportunities or design-around strategies.
FAQs
Q1: What is the primary inventive aspect of JP2015034167?
A: The patent’s inventive core lies in a specific manufacturing process for pharmaceutical compositions—focusing on process steps, parameters, or techniques that improve drug stability or bioavailability.
Q2: Can this patent be enforced against generic manufacturers?
A: Yes, if their manufacturing methods infringe upon the specific process claims, enforcement actions could be initiated under Japanese patent law.
Q3: How broad are the claims within JP2015034167?
A: The claims are designed to be sufficiently broad to cover various process modifications but are usually limited to specific process parameters and conditions.
Q4: How does this patent landscape compare globally?
A: Similar process patents exist worldwide, often as part of international patent families to extend protection—Japan strategically aligns with global patent efforts, especially in the Asia-Pacific region.
Q5: What is the key strategic value of this patent for a pharmaceutical company?
A: It provides process exclusivity, securing market position, facilitating regulatory approval, and deterring competitors from copying the manufacturing method.
